MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Retinal Degeneration
    • Publications
  • News & Media
  • Contact Us
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Retinal Degeneration
    • Publications
  • News & Media
  • Contact Us
  •  
  • Uncategorized
  • AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
  • Previous
  • Next

AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

0 comments

About the Author

user

user

Related Posts

AIVITA Biomedical Closes $25 Million Financing Round
AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy
AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management
AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research

More From This Category

AIVITA Biomedical Closes $25 Million Financing Round
AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy
AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management
AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research
  • Previous
  • Next

Recent Posts

  • AIVITA Biomedical Closes $25 Million Financing Round
  • AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
  • AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy
  • AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management
  • AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research

Recent Comments

    Archives

    • December 2020
    • November 2020
    • August 2020
    • July 2020
    • April 2020
    • February 2020
    • January 2020
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • December 2017
    • November 2017
    • September 2017
    • June 2017
    • May 2017
    • April 2017
    • February 2017
    • September 2016
    • July 2016
    • June 2016

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    AIVITA Biomedical is an immuno-oncology company designing personalized vaccines that target the seed of all cancers: tumor-initiating cells. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer and other fields.

    Recent News

    • AIVITA Biomedical Closes $25 Million Financing Round
    • AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
    • AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy
    • AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management
    • AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research

    Site Navigation

    • About Us
    • Programs
    • News & Media
    • Contact Us
    Copyright © 2020 | AIVITA Biomedical, Inc.